Holen Sie sich die Stockscreener-App
6.18
0.98%
0.06
Handel nachbörslich:
6.25
0.07
+1.13%
Schlusskurs vom Vortag:
$6.12
Offen:
$6.13
24-Stunden-Volumen:
377.68K
Relative Volume:
0.91
Marktkapitalisierung:
$132.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.54M
KGV:
-3.9871
EPS:
-1.55
Netto-Cashflow:
$-18.30M
1W Leistung:
+6.55%
1M Leistung:
-5.21%
6M Leistung:
+14.87%
1J Leistung:
+729.64%
1-Tages-Spanne:
$6.00
$6.35
1-Wochen-Bereich:
$5.36
$6.35
52-Wochen-Spanne:
$0.45
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Firmenname
Unicycive Therapeutics Inc
Sektor
Branche
Telefon
650-384-0642
Adresse
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Vergleichen Sie UNCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.18 | 131.53M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Eingeleitet | Guggenheim | Buy |
| 2024-04-04 | Eingeleitet | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Aktie (UNCY) Neueste Nachrichten
Will Unicycive Therapeutics Inc. stock maintain momentum in 2025July 2025 Earnings & Fast Moving Trade Plans - ulpravda.ru
Can Unicycive Therapeutics Inc. stock continue upward trendQuarterly Portfolio Review & Capital Efficiency Focused Ideas - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
News | Unicycive Therapeutics leases Mountain View offices - CoStar
How interest rate cuts could boost Unicycive Therapeutics Inc. stockMarket Trend Summary & Consistent Profit Trading Strategies - ulpravda.ru
How geopolitical tensions affect Unicycive Therapeutics Inc. stockBull Market Opportunities & Minimal Capital Investment - ulpravda.ru
Unicycive Therapeutics : January 2026 Corporate Presentation - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
UNCY Stock Price, Forecast & Analysis | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - Chartmill
What drives Unicycive Therapeutics Inc stock priceTrendline Breakouts & Let Our AI Be Your Trading Assistant - earlytimes.in
Maxim Group Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Guggenheim reiterates Buy rating on Unicycive stock amid NDA resubmission By Investing.com - Investing.com UK
Unicycive Therapeutics seeks FDA approval — again — for dialysis patients' phosphate treatment - The Business Journals
Unicycive resubmits NDA for hyperphosphatemia asset - Seeking Alpha
Unicycive Therapeutics announces resubmission of new drug application (NDA) for oxylanthanum carbonate (OLC) - MarketScreener
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - TradingView — Track All Markets
Unicycive Resubmits New Drug Application for Oxylanthanum Carbonate - MarketScreener
Unicycive resubmits NDA for kidney disease treatment to FDA - Investing.com
Unicycive Therapeutics Resubmits NDA for Oxylanthanum Carbonate to FDA for Chronic Kidney Disease Treatment - Quiver Quantitative
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum ... - Caledonian Record
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate - MarketScreener
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth - Yahoo Finance
Rally Mode: Can Unicycive Therapeutics Inc stock continue upward trendJuly 2025 Outlook & Fast Moving Stock Trade Plans - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Connect - ACCESS Newswire
Why Unicycive Therapeutics Inc. stock is a must watch in 2025Trade Risk Summary & Verified Stock Trade Ideas - Улправда
Is Unicycive Therapeutics Inc. stock a top momentum playLong Setup & Smart Investment Allocation Insights - Улправда
Will Unicycive Therapeutics Inc. stock remain a Wall Street favorite2025 Biggest Moves & Long-Term Growth Stock Strategies - Bollywood Helpline
How Unicycive Therapeutics Inc. stock performs after earningsWeekly Market Outlook & High Accuracy Swing Trade Signals - Улправда
How Unicycive Therapeutics Inc. stock benefits from tech adoptionLong Setup & Daily Technical Forecast Reports - Улправда
Will Unicycive Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Summary & Long-Term Growth Plans - Bölüm Sonu Canavarı
Can Unicycive Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Weekly Recap & Consistent Profit Alerts - Улправда
Why analysts upgrade Unicycive Therapeutics Inc. stockEarnings Performance Report & Fast Exit Strategy with Risk Control - DonanımHaber
Aug Summary: Why Unicycive Therapeutics Inc. stock is a must watch in 20252025 Volume Leaders & Daily Technical Stock Forecast Reports - Улправда
Bragar Eagel & Squire is Investigating Certain Officers and - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Chart Watch: Why analysts upgrade Unicycive Therapeutics Inc stock2025 Market Trends & Consistent Return Strategy Ideas - moha.gov.vn
Unicycive is all-in on kidney care, focusing on underserved areas: CEO - AlphaStreet
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (UNCY) price target decreased by 12.88% to 47.43 - MSN
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Vivo Capital LLC Has $5.42 Million Stock Position in Unicycive Therapeutics, Inc. $UNCY - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Trading Up 5.6%Time to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Important Notice to Long-Term Shareholders of Five Below, - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out - ACCESS Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Finanzdaten der Unicycive Therapeutics Inc-Aktie (UNCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):